文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

接受抑制性抗逆转录病毒治疗的人类免疫缺陷病毒感染者双剂新冠疫苗接种后抗体持久性典型且第三剂应答强烈

People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses.
PubMed 文献 · J Infect Dis · 2023-01-01

在99例接受抑制性抗逆转录病毒治疗的人类免疫缺陷病毒(HIV)感染者和152例对照中,双剂新冠疫苗接种后6个月内抗体应答自然下降,但校正社会人口学、健康和疫苗相关因素后,感染者抗体浓度和下降速率与对照无差异,对Omicron的中和应答也未见更差,低CD4+ T细胞最低值亦未损害应答。第三剂后体液应答显著超过第二剂后水平,感染者与对照相当或更高,mRNA-1273第三剂是与较高第三剂后应答最强的一致相关因素。

要点

  • 双剂疫苗接种后6个月内,感染者与对照的抗体浓度和下降速率无差异。
  • 第三剂后应答显著超过第二剂后水平,感染者与对照相当或更高。
  • mRNA-1273第三剂是与较高第三剂后应答最强的一致相关因素。

核心结论

  • 接受抑制性抗逆转录病毒治疗的HIV感染者接种2剂和3剂新冠疫苗后均产生强烈抗体应答,结果强调第三剂在Omicron背景下的免疫益处。

研究设计与样本

  • 在99例接受抑制性抗逆转录病毒治疗的HIV感染者和152例对照中,测量双剂疫苗接种后至6个月及第三剂后1个月针对SARS-CoV-2刺突蛋白受体结合域的抗体、ACE2置换及对野生型和Omicron株的病毒中和。

主要发现

  • 双剂疫苗接种后体液应答自然下降,但校正社会人口学、健康和疫苗相关因素后,未发现感染者抗体浓度更低或下降速率更快的证据。
  • 未发现感染者双剂后病毒中和更差,也未发现低CD4+ T细胞最低值损害应答的证据。
  • 第三剂后体液应答显著超过第二剂后水平,但Omicron特异性应答始终弱于针对野生型病毒的应答。
  • 第三剂后感染者应答与对照相当或更高。
  • mRNA-1273第三剂是与较高第三剂后应答最强的一致相关因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Longer-term humoral responses to 2-dose coronavirus disease 2019 (COVID-19) vaccines remain incompletely characterized in people living with human immunodeficiency virus (HIV) (PLWH), as do initial responses to a third dose. METHODS: We measured antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain, angiotensin-converting enzyme 2 (ACE2) displacement, and viral neutralization against wild-type and Omicron strains up to 6 months after 2-dose vaccination, and 1 month after the third dose, in 99 PLWH receiving suppressive antiretroviral therapy and 152 controls. RESULTS: Although humoral responses naturally decline after 2-dose vaccination, we found no evidence of lower antibody concentrations or faster rates of antibody decline in PLWH compared with controls after accounting for sociodemographic, health, and vaccine-related factors. We also found no evidence of poorer viral neutralization in PLWH after 2 doses, nor evidence that a low nadir CD4+ T-cell count compromised responses. Post-third-dose humoral responses substantially exceeded post-second-dose levels, though Omicron-specific responses were consistently weaker than responses against wild-type virus. Nevertheless, post-third-dose responses in PLWH were comparable to or higher than controls. An mRNA-1273 third dose was the strongest consistent correlate of higher post-third-dose responses. CONCLUSION: PLWH receiving suppressive antiretroviral therapy mount strong antibody responses after 2- and 3-dose COVID-19 vaccination. Results underscore the immune benefits of third doses in light of Omicron.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lapointe HR, Mwimanzi F, Cheung PK, et al. People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. J Infect Dis. 2023. PMID: 35668700. doi:10.1093/infdis/jiac229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。